

FILE 'HOME' ENTERED AT 13:35:22 ON 03 SEP 2002

>> FI Caplus
COST IN U.S. DOLLARS SINCE FILE
TOTAL

the CAS Rates (Saurus (RL field) in this file.

>> A 154486-25-6
S 154486-25-6
O 154486-25-6D
L1 154486-25-6/RN (154486-25-6D)
S 154486-25-6D (NOTL) 154486-25-6D)

>> d 1-5

L1 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002
ACS
AN 2000-707018 CAPLUS
DN 133-280556
TI Adjuvant compositions and methods for enhancing
immune response to
polynucleotide-based vaccines
IN Wheeler, Carl J.
PA Vical Incorporated, USA
SO PCT Int. Appl. 72 pp
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 2000057917 A2 20001005 WO 2000-
US282 20000324
WO 2000057917 A3 20010104
W. CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL,
PT, SE
EP 116140 A2 20020102 EP 2000-919777
20000324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI,
LU, NL, SE, MC, PT,
IE, FI
PRAI US 1999-126340 P 19990326
WO 2000-US282 W 20000324

L1 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002
ACS
AN 2000-455564 CAPLUS
DN 133-103732
TI Treatment of viral diseases using an interferon
onco-gene-expressing
polynucleotide
IN Parker, Suzannee, Horton, Holly
PA Vical Incorporated, USA
SO PCT Int. Appl. 52 pp
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 2000040273 A2 20000713 WO 1999-
US30843 19991228
WO 2000040273 A3 20001116
W. CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL,
PT, SE
PRAI US 1999-115403 P 19990108

L1 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002
ACS
AN 1999-355754 CAPLUS
DN 131-18016
TI Treatment of cancer using cytokine-expressing
polynucleotides and
compositions thereof
IN Horton, Holly, Parker, Suzannee, Manthorpe, Marston,
Felgner, Philip
PA Vical, Inc., USA
SO PCT Int. Appl. 188 pp
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 9926663 A2 19990603 WO 1998-
US24830 19981120
WO 9926663 A3 20000106
W. CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL,
PT, SE
CA 2309766 AA 19990603 CA 1998-2309766
19981120
EP 1032428 A2 20000906 EP 1998-960333
19981120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI,
LU, NL, SE, MC, PT,
IE, FI
JP 2001123480 T2 20011127 JP 2000-521864
19981120
PRAI US 1997-67087 P 19971120

US 1998-79914P P 19980330
US 1998-100320P P 19980915
WO 1998-US24830 W 19981120

L1 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002
ACS
AN 1998-351799 CAPLUS
DN 129-36461
TI Complexes of adenovirus with cationic molecules for
gene therapy
IN Weiss, Michael J.; Pasbender, Allen J.
PA University of Iowa Research Foundation, USA
SO PCT Int. Appl. 57 pp
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 9822144 A2 19980528 WO 1997-
US21496 19971120
WO 9822144 A3 19980709
W. AU, CA, JP
RW: AT, BE, CH, DR, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE
US 5962429 A 19991005 US 1996-755035
19961122
AU 9853615 A1 19980610 AU 1998-53615
19971120
PRAI US 1996-755035 19961122
WO 1997-US21496 19971120

L1 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002
ACS
AN 1996-200633 CAPLUS
DN 124-279113
TI Converting an alcohol to an amine is a cationic lipid
dramatically alters
the co-lipid requirement, cellular transfection activity
and the
ultrastructure of DNA-lysosome complexes
IN Wheeler, Carl J.; Salha, Loreta; Yang, Guiling;
Tzai, Yali; Bhatnagar,
Carlos; Felgner, Philip; Norman, Jon; Manthorpe, Marston
CS Vical Incorporated, Suite 100, 9373 Towne Centre
Drive, San Diego, CA,
92121, USA
SO Biochimica et Biophysica Acta (1996), 1280(1), 1-11
CODEN: BBACAQ; ISSN: 0006-3002
PB Elevator
DT Journal
LA English
>> s dmrie/rn
L2 154 DMRIE/RN
(DMRIE)

>> s l2 and vaccine
34998 VACCINE
34441 VACCINES
43800 VACCINE
(VACCINE OR VACCINES)
L3 19 L2 AND VACCINE

>> s l3 and rsv
2751 RSV
18 RSVS
2754 RSV
(RSV OR RSVS)
L4 1 L3 AND RSV

>> d
L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002
ACS
AN 1998-249878 CAPLUS
DN 129-12373
TI Transfection of primary tumor cells and tumor cell
lines with plasmid
DNA/lipid complexes
AU Sipeck, Alison T.; Herd, Evan M.; Brailey,
Jacqueline L.; Clark, Paul
R.; Norman, Jon; Parker, Suzanne E.
CS Arizona Cancer Center, Tucson, AZ, 85724-5024,
USA
SO Cancer Gene Therapy (1998), 5(2), 119-126
CODEN: COTGHE; ISSN: 0929-1903
PB Appleton & Lange
DT Journal
LA English

>> d ab
L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002
ACS
AB Cancer ***vaccine*** that utilize genetically
modified tumor cells
require gene transfer methods capable of producing
immunostimulatory doses
of transgenes from fresh or short-term cultures of human
tumor cells. Our
studies optimize in vitro transfection of primary tumor
cells using
cationic lipids and a plasmid encoding the gene for
human interleukin-2
(IL-2). Established tumor cell lines produced 10- to
100-fold more IL-2
than did fresh or short-term tumor cultures as measured
by enzyme-linked

immunoassay. Importantly, transfection of
primary tumor cells
produced immunostimulatory levels of IL-2 as detd. by
increased thymidine
incorporation by autologous peripheral blood
mononuclear cells and
lymphokine-activated killer cell activity. IL-2 secretion
by tumor cells
persisted for at least 30 days post-transfection and was
unaffected by
freeze thawing or irradi. to 8000 rads. Multiple solid
tumor types were
successfully transfected, but normal blood mononuclear
cells and leukocytes
blasts were resistant to transfection. Enzyme-linked
immunoassay
anal. of the amt. of IL-2 secreted into the medium by
transfected tumor
cells correlated with the percentage of tumor cells
expressing
intracellular IL-2 as measured by flow cytometry.
Plasmids utilizing a
cytomegalovirus promoter yielded superior transfection
efficiencies
compared with plasmids contg. a Rous sarcoma virus
promoter. These
results suggest that a clin. ***vaccine*** trial using
autologous
tumor cells genetically modified to secrete IL-2 is
feasible in patients
with solid tumors.

>> d l kwic

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002
ACS
AB Cancer ***vaccine*** that utilize genetically
modified tumor cells
require gene transfer methods capable of producing
immunostimulatory doses
of transgenes from fresh or . . . promoter yielded
superior transfection
efficiencies compared with plasmids contg. a Rous
sarcoma virus promoter.
These results suggest that a clin. ***vaccine*** trial
using
autologous tumor cells genetically modified to secrete
IL-2 is feasible in
patients with solid tumors.
ST cancer ***vaccine*** transfection IL2 plasmid
lipid; cationic lipid
plasmid transfection cancer ***vaccine***;
interleukin 2 plasmid
transfection cancer ***vaccine***; gene therapy
cancer interleukin 2
plasmid
IT Promoter (genetic element)
RL: BFR (Biological process); BSU (Biological study,
unclassified); THU
(Therapeutic use); BIOL (Biological study); PROC
(Process); USES (Uses)
(CMV or ***RSV***; primary tumor cell and
tumor cell line
transfection with IL-2-encoding plasmid
DNA/cationic lipid complexes)
IT ***Vaccines***
(tumor; primary tumor cell and tumor cell line
transfection with
IL-2-encoding plasmid DNA/cationic lipid complexes)
IT Antitumor agents
(***vaccines***; primary tumor cell and tumor cell
line
transfection with IL-2-encoding plasmid
DNA/cationic lipid complexes)
IT 2462-83-7; Dope 15312-64-2, ***DMRIE***
RL: THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(primary tumor cell and tumor cell line transfection
with IL-2-encoding
plasmid DNA/cationic lipid complexes)

>> d his

(FILE 'HOME' ENTERED AT 13:35:22 ON 03 SEP
2002)

FILE 'CAPLUS' ENTERED AT 13:38:15 ON 03 SEP
2002
L1 S 154486-25-6/RN
L2 154 S DMRIE/RN
L3 19 S L2 AND VACCINE
L4 1 S L2 AND RSV

>> d l3 1-19 i so

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002
ACS
TI Polymer combinations that result in stabilized aerosols
for gene delivery
to the lungs
SO PCT Int. Appl. 136 pp
CODEN: PIXXD2

L1 ANSWER 2 OF 1 CAPLUS COPYRIGHT 2002
ACS
TI ***Vaccine*** against foot-and-mouth disease
SO PCT Int. Appl. 79 pp
CODEN: PIXXD2

L3 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
 SO PCT Int. Appl. 176 pp.
 CODEN: PIXXD2

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Improved DNA ***vaccine*** for livestock
 SO PCT Int. Appl. 79 pp.
 CODEN: PIXXD2

L3 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
 SO Blood (2001), 98(1), 49-56
 CODEN: BLOODAW; ISSN: 0006-4971

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Prevention of myocardial, abortion and intrasternal infection associated with porcine circovirus-2
 SO PCT Int. Appl. 133 pp.
 CODEN: PIXXD2

L3 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Lipid-nucleic acid compositions for stimulating cytokine secretion and inducing an immune response
 SO PCT Int. Appl. 94 pp.
 CODEN: PIXXD2

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/ ***DMRIE*** /DOPE lipid complex
 SO Current Opinion in Molecular Therapeutics (2001), 3(1), 70-76
 CODEN: CUOTOF; ISSN: 1464-8431

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 cDNAs encoding the FR-3 receptor ligand and there use as adjuvants in vector ***vaccines***
 SO PCT Int. Appl. 148 pp.
 CODEN: PIXXD2

L3 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Potent calciviruses genes and ***vaccine***, in particular recombinant ***vaccine***
 SO PCT Int. Appl. 61 pp.
 CODEN: PIXXD2

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Porcine circovirus ***vaccine***
 SO PCT Int. Appl. 40 pp.
 CODEN: PIXXD2

L3 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 DNA ***vaccine*** against Paratyphoidiae for pets and game animals and their delivery in liposomes containing cationic lipids
 SO PCT Int. Appl. 110 pp.
 CODEN: PIXXD2

L3 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Cytosolfin dimers and methods of use thereof
 SO PCT Int. Appl. 50 pp.
 CODEN: PIXXD2

L3 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Adjuvant compositions and methods for enhancing immune response to polynucleotide-based ***vaccines***
 SO PCT Int. Appl. 72 pp.
 CODEN: PIXXD2

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Effectiveness of combined interferon 2 and B7.1 vaccination strategy is dependent on the sequence and order: A liposome-mediated gene therapy treatment for bladder cancer
 SO Clinical Cancer Research (2000), 6(7), 2913-2920
 CODEN: CCREF4; ISSN: 1078-0432

L3 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Adjuvants for plasmid DNA ***vaccines***
 SO Methods in Molecular Medicine (2000), 29, 185-196
 CODEN: MMMEFN

L3 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
 SO Journal of Immunology (1999), 162(1), 254-262
 CODEN: JOMMAD; ISSN: 0022-1767

L3 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA
 SO Antisense & Nucleic Acid Drug Development (1998), 8(5), 401-414
 CODEN: ANADFS; ISSN: 1087-2906

L3 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2002 ACS
 T1 Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes
 SO Cancer Gene Therapy (1998), 5(2), 119-126
 CODEN: CGTHEG; ISSN: 0929-1903

=> d 16-18 ab
 1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE. The answer numbers requested are not in the answer set. ENTER ANSWER NUMBER OR RANGE (1):1

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
 AB Cancer ***vaccine*** that utilize genetically modified tumor cells require gene transfer methods capable of producing immunostimulatory doses of transgenes from fresh or short-term cultures of human tumor cells. Our studies optimize in vitro transfection of primary tumor cells using cationic lipids and a plasmid encoding the gene for human interleukin-2 (IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2 than did fresh or short-term tumor cultures as measured by enzyme-linked immunosorbent assay. Importantly, transfection of primary tumor cells produced immunostimulatory levels of IL-2 as tested by increased thymidine incorporation by autologous peripheral blood mononuclear cells and lymphokine-activated killer cell activity. IL-2 secretion by tumor cells persisted for at least 30 days post-transfection and was unaffected by freeze thawing or irradiation to 8000 rads. Multiple solid tumor types were successfully transfected, but normal blood mononuclear cells and leukemic blasts were resistant to transfection. Enzyme-linked immunosorbent assay of the amount of IL-2 secreted into the medium by transfected tumor cells correlated with the percentage of tumor cells expressing intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a cytomegalovirus promoter yielded superior transfection efficiencies compared with plasmids containing a Rous sarcoma virus promoter. These results suggest that a clinical ***vaccine*** trial using autologous tumor cells genetically modified to secrete IL-2 is feasible in patients with solid tumors.

=> d 13 16-18 ab
 L3 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AB A review with 38 refs. discussing the effects of the co-injection of bevacizumab (BP), polyvinyl pyrrolidone (PVP), or ***DMRIE*** /DOPE cationic liposomes on plasmid DNA-mediated luciferase gene expression and antibody responses to influenza nucleoprotein (NP) antigen.

L3 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AB The development of ***vaccine*** against pathogens transmitted across the genito-rectal mucosa that effectively stimulate both secretory IgA Aha and cytotoxic T lymphocytes in the genital tract and CTL in the draining lymph nodes (LN) has proven a major challenge. Here we report a novel, noninvasive approach of genetic vaccination via the intranasal route. Such vaccination elicits immune responses in the genital and rectal mucosa, draining LNs, and central lymphoid system. Intranasal immunization with plasmid DNA-lipid complexes encoding the model Ag

directly luciferase resulted in dissemination of the DNA and the encoded transcript throughout the respiratory and gastrointestinal tracts, draining LNs, and spleen. Complexing the plasmid DNA with the lipid ***DMRIE*** /DOPE enhanced expression of the encoded protein in the respiratory tract, increased specific secretory IgA Aha in the vaginal and rectal tracts, and increased the circulating levels of specific IgA and IgG. In addition, intranasal DNA immunization resulted in generation of Ag-specific CTL that were localized in the genital and cervical LNs and spleen. These results suggest that intranasal immunization with plasmid DNA-lipid complexes may represent a generic immunization strategy against pathogens transmitted across the genito-rectal and other mucosal surfaces.

L3 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2002 ACS
 AB Direct gene transfer into the respiratory system could be carried out for either the apneustic or immunization purposes. Here we demonstrate that cells in the lung can take up and express plasmid DNA encoding a luciferase reporter gene whether it is administered in naked form or formulated with cationic liposomes. Depending on the lipid used, the transfection efficiency with liposome-formulated DNA may be higher, the same as, or less than that with pure plasmid DNA. Tetraethylethylenediamine analogs with alkyl groups of 16 or 18 carbons and ***DMRIE*** /cholesterol formulations proved particularly effective. Similar results for reporter gene expression in the lung were obtained whether the DNA (naked or lipid formulated) was administered by indirect, non-invasive intranasal delivery (inhaled or instilled) or by invasive, direct intratracheal delivery (injected or via a cannula). Reporter gene expression peaks around 4 days, then falls off dramatically by 9 days. The dose-response is linear, at least up to 100 µg plasmid DNA, suggesting better transfection efficiencies might be realized if there was not a vol. limitation. For a given dose of DNA, the best results are obtained when the DNA is mixed with the min. amt. of lipid that can complex it completely. These results are discussed in the context of direct gene transfer for either gene therapy or delivery of a mucosal DNA ***vaccine***.

=> s 153312-4-2/m or 154486-25-6/m
 0 153312-4-2/RN
 (153312-4-2)
 5 154486-25-6
 0 154486-25-0D
 5 154486-25-6/RN
 (154486-25-6 (NOTL) 154486-25-6D)

L5 5 153312-4-2/RN or 154486-25-6/RN

=> s 153312-64-2/m or 154486-25-6/m
 111 153312-64-2
 6 153312-64-2D
 105 153312-64-2/RN
 (153312-64-2 (NOTL) 153312-64-2D)
 5 154486-25-6
 0 154486-25-0D
 5 154486-25-6/RN
 (154486-25-6 (NOTL) 154486-25-6D)

L6 105 153312-64-2/RN or 154486-25-6/RN

=> s 16 and (rev or brev)
 2751 RSV
 18 RSVS
 2754 RSV
 (RSV OR RSVS)
 110 BRVS
 1 BRVS
 110 BRVS
 (BRVS OR BRVS)
 L7 5 L6 AND (RSV OR BRVS)

=> dup rem 17
 PROCESSING COMPLETED FOR L7
 L8 4 DUP REM L7 (1 DUPLICATE REMOVED)

=> d 1-4 m 0

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
 T1 Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes
 SO Cancer Gene Therapy (1998), 5(2), 119-126
 CODEN: CGTHEG; ISSN: 0929-1903

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002

ACS DUPLICATE I

T1 Cationic liposome-mediated expression of HIV-regulated luciferase and diphtheria toxin A genes in HeLa cells infected with or expressing HIV
SO Biochimica et Biophysica Acta (1997), 1356(2), 185-197
CODEN: BBACQJ, ISSN: 0006-3002

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002

ACS

T1 Plasmids suitable for gene therapy

SO PCT Int. Appl., 50 pp.

CODEN: FICXDX2

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002

ACS

T1 Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations

SO J. Biol. Chem. (1994), 269(4), 2550-61

CODEN: JBCHAS, ISSN: 0021-9258

--> d 1-4 b

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002

ACS

AB Cancer vaccines that utilize genetically modified tumor cells require gene transfer methods capable of producing immunostimulatory doses of

transgenes from fresh or short-term cultures of human tumor cells. Our studies optimize in vitro transfection of primary tumor

cells using cationic lipids and a plasmid encoding the gene for human interleukin-2

(IL-2). Established tumor cell lines produced 10- to 100-fold more IL-2

than did fresh or short-term tumor cultures as measured by enzyme-linked immunosorbent assay. Importantly, transfection of

primary tumor cells produced immunostimulatory levels of IL-2 as determined by increased thymidine

incorporation by autologous peripheral blood mononuclear cells and

lymphokine-activated killer cell activity. IL-2 secretion by tumor cells

persisted for at least 30 days post-transfection and was unaffected by

freeze thawing or irradiation to 8000 rads. Multiple solid tumor types were

successfully transfected, but normal blood mononuclear cells and leukemic

blasts were resistant to transfection. Enzyme-linked immunosorbent

assay of the amount of IL-2 secreted into the medium by transfected tumor

cells correlated with the percentage of tumor cells expressing

intracellular IL-2 as measured by flow cytometry. Plasmids utilizing a

cytomegalovirus promoter yielded superior transfection efficiencies

compared with plasmids containing a Rous sarcoma virus promoter. These

results suggest that a clinical vaccine trial using autologous tumor cells

genetically modified to secrete IL-2 is feasible in patients with solid

tumors.

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002

ACS DUPLICATE I

AB HIV-regulated expression of the diphtheria toxin A fragment gene

(HIV-DT-A) is a potential gene therapy approach to AIDS. Since cationic

liposomes are safe and non-immunogenic for in vivo gene delivery, the

authors examined whether LipofectAMINE or DMRIE reagent could mediate the

transfection of HIV-DT-A (pTHA43) or the HIV-regulated luciferase gene

(pLUC43) into HIV-infected or uninfected HeLa cells. pLUC43 was

expressed at a 103-fold higher level in HeLa/LAV cells than in uninfected

HeLa cells, while the extent of expression of ***RSV***-regulated

luciferase was the same in both cell lines. Co-transfection of HeLa cells

with pTHA43 and the proviral HIV clone, HXB.DELTA.Bgl, resulted in

complete inhibition of virus production. In contrast, the delivery of HIV-DT-A

to chronically infected HeLa/LAV or HeLa/IIIIB cells, or to HeLa CD4+ cells

before infection, did not have a specific effect on virus production, since

treatment of cells with control plasmids also reduced virus production. This

result could be ascribed to cytotoxicity of the reagents. The efficiency

of transfection, as measured by the percentage of cells expressing

beta-gal, was approx. 5. Thus, cationic liposome-mediated transfection

was too inefficient to inhibit virus production when the DT-A

was delivered by cationic liposomes to chronically- or de novo-infected cells. However,

when both the virus and DT-A genes were delivered into the same cells by

cationic liposomes, DT-A was very effective at inhibiting virus production.

The results indicate that the successful use of cationic liposomes for

gene therapy will require the improvement of their transfection efficiency.

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002

ACS

AB The invention provides vectors adapted for use in transfecting into tissue

or cells of an organism genetic material, encoding one or more cistrons

capable of expressing one or more immunogenic or therapeutic peptides and

related methods. Preparation of a HLA-B7-encoding plasmid that contains the

origin of replication of pBR322, the ***RSV*** LTR promoter, SV40

polyadenylation signal, etc. methods for transfection using cationic

lipid formulations comprising DMRIE/DOPE, and its use in gene therapy are

also described.

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002

ACS

AB Studies are reported which examined the effects of some synthetic chem.

structural changes in both the cationic amphiphile and the neutral

phospholipid components of liposomes on their biological activity. Cationic

and neutral phospholipids were formulated together as large multilamellar

vesicles or small sonicated unilamellar vesicles in water, and each

formulation was assayed quantitatively in 96-well microtiter plates under 64

different assay conditions using COS-7 cells and an ***RSV***

-beta-galactosidase expression plasmid. The cationic lipid moiety used

was derived from a novel series of 2,3-dialkylxypropyl quaternary

ammonium compounds containing a hydroxyalkyl moiety on the quaternary amine. A

homologous series of dioleoylalkyl (C18:1) compounds containing increasing

hydroxyalkyl chain lengths on the quaternary amine were formulated with 50

mol % dioleoylphosphatidylmethanolamine (DOPE) and assayed for transfection

activity. The order of efficacy was Et > Pr > Bu > pentyl >

2,3-dioleoylxypropyl-1-trimethyl ammonium bromide (DOTMA). The order of

transfection efficiency for a similarly formulated homologous series of

hydroxyethyl quaternary ammonium salts with different alkyl chain

substituents was dimethyl > dioleoyl > dipalmitoyl > distearyl. Addition of

100 mM chloroquine in the transfection experiment enhanced the activity of

the dioleoyl compound by 4-fold and decreased the activity of the dimethyl

compound by 70%. For each of the compounds and formulations examined, large

multilamellar vesicles were more active than small unilamellar vesicles.

The neutral phospholipid requirements for transfection were also examined.

Cationic vesicles formulated with 50 mol % DOPE were 2-5-fold more active

than formulations with 50 mol % dioleoylphosphatidylcholine or

formulations without any neutral lipid, and the level of DOPE required for

optimal activity was 50 mol %. DOPE analogs with increasing acyl chain

lengths were progressively less active than unsaturated analogs, analogs with

increasing numbers of Me or methylene groups added to the primary amine were

also progressively less active. The lyophosphatidylethanolamine analogs

examined neither enhanced nor inhibited the activity of these reagents.

These results have implications regarding the design of new cationic and

neutral lipid models for use in the development of improved cationic lipid

gene delivery vectors.

--> d 3

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002

ACS

AN 1995:468668 CAPLUS

DN 123:102758

T1 Plasmids suitable for gene therapy

IN Nabel, Gary J.; Nabel, Elizabeth O.; Lew, Denise; Marquet, Magda

PA. Vical Inc., USA; Regents of the University of

Michigan

SO PCT Int. Appl., 50 pp.

CODEN: FICXDX2

DT Patent

LA English

PAN CNT 2

PATENT NO.

KIND DATE

APPLICATION

NO. DATE

PI WO 9429469 A2 19941222 WO 1994-

US6069 19940527

WO 9429469 A3 19950323

W. CA, JP, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,

LU, MC, NL, PT, SE

EP 702722 A1 19960327 EP 1994-919290

19940527

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,

LU, MC, NL, PT, SE

US 5910488 A 19990608 US 1995-564313

19951201

PRAI US 1993-74344 19930607

WO 1994-US6069 19940527

--> RSV (S) vaccine

2751 RSV

18 RSVS

2754 RSV

(RSV OR RSVS)

34958 VACCINE

34441 VACCINES

43800 VACCINE

(VACCINE OR VACCINES)

L9 191 RSV (S) VACCINE

--> S 19 and (bovine or cow)

140332 BOVINE

541 BOVINES

140703 BOVINE

(BOVINE OR BOVINES)

28401 COW

28351 COWS

45109 COW

(COW OR COWS)

L10 21 L9 AND (BOVINE OR COW)

--> d 1-21 b

L10 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2002

ACS

T1 Non-glycosylated peptides derived from the G attachment glycoprotein of

respiratory syncytial virus for use as antigens in vaccines

SO PCT Int. Appl., 27 pp.
CODEN: FICXDX2

L10 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2002

ACS

T1 Respiratory syncytial virus (RSV) nonstructural (NS) proteins as host

range determinants: a chimeric ***bovine*** RSV with NS genes from

human RSV is attenuated in interferon-competent ***bovine*** cells

SO Journal of Virology (2002), 76(9), 4287-4293
CODEN: JOVIAH, ISSN: 0022-538X

L10 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2002

ACS

T1 Mucosal immunization of rhesus monkeys against respiratory syncytial virus

subgroups A and B and human parainfluenza virus type 3 by using a live

cDNA-derived vaccine based on a host range-attenuated ***bovine***

parainfluenza virus type 3 vector backbone
SO Journal of Virology (2002), 76(3), 1059-1099
CODEN: JOVIAH, ISSN: 0022-538X

L10 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2002

ACS

T1 Respiratory syncytial virus vaccines expressing protective antigens from

promoter-primordial genes
SO PCT Int. Appl., 148 pp.
CODEN: FICXDX2

L10 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2002

ACS

T1 Formation of infectious respiratory syncytial virus particles by

expression of cloned viral genes
SO U.S., 24 pp.
CODEN: USXXAM

L10 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2002

ACS

T1 Production of attenuated, human- ***bovine*** chimeric respiratory

syncytial virus vaccines
SO PCT Int. Appl., 148 pp.
CODEN: FICXDX2

L10 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2002

ACS

T1 Attenuated respiratory syncytial virus vaccines involving modification of

M2 ORF2
SO PCT Int. Appl., 124 pp.

CODEN: PIXXD2

L10 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Plant-derived antigens against respiratory syncytial virus
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2

L10 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Production of attenuated chimeric respiratory syncytial virus vaccines
from cloned nucleotide sequences
SO PCT Int. Appl., 280 pp.
CODEN: PIXXD2

L10 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Chimeric ***bovine*** respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects
on host range and evaluation as a live-attenuated HRSV vaccine
SO Journal of Virology (2000), 74(3), 1187-1199
CODEN: JOVIAM; ISSN: 0022-538X

L10 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Identification of a conserved neutralization site in the first heptad repeat of the fusion protein of respiratory syncytial virus
SO Archives of Virology (1998), 143(2), 313-320
CODEN: ARVIDV; ISSN: 0304-8688

L10 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV
SO Vaccine (1997), 15(17/18), 1908-1916
CODEN: VACCDE; ISSN: 0264-410X

L10 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of ***bovine*** respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions
SO Journal of General Virology (1997), 78(12), 3195-3206
CODEN: JGVIAV; ISSN: 0022-1317

L10 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI In vivo and in vitro packaging of infectious respiratory syncytial virus using cloned viral nucleic acids
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2

L10 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Phosphoprotein profile analysis of ruminant respiratory syncytial virus isolates
SO American Journal of Veterinary Research (1997), 58(5), 478-481
CODEN: AJVRAH; ISSN: 0002-9645

L10 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Stabilization of respiratory syncytial virus (***RSV***) against thermal inactivation and freeze-thaw cycles for development and control of ***RSV*** and immune globulin
SO Vaccine (1996), 14(15), 1417-1420
CODEN: VACCDE; ISSN: 0264-410X

L10 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Immune responses of lambs to the fusion (F) glycoprotein of ***bovine*** respiratory syncytial virus expressed on insect cells infected with a recombinant baculovirus
SO Vaccine (1996), 14(8), 773-779
CODEN: VACCDE; ISSN: 0264-410X

L10 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Antigenic peptides derived from the G protein of respiratory syncytial virus for type- and subtype-specific diagnosis of infection
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2

L10 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes
SO Virology (1995), 208(2), 478-484
CODEN: VIRLAX; ISSN: 0042-6822

L10 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Human respiratory syncytial virus vaccine derived from the 1A (9.5 kd) protein
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2

L10 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Murine cytotoxic T cells specific to respiratory syncytial virus recognize different antigenic subtypes of the virus
SO J. Gen. Virol. (1986), 67(4), 923-9
CODEN: JGVIAV; ISSN: 0022-1317

=> d 13 ab

L10 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002
AB The immunogenicity and protective efficacy of recombinant vaccinia viruses (rVV) encoding the F, G, N, or M2 (22K) proteins of ***bovine*** respiratory syncytial virus (BRSV) were evaluated in calves, the natural host for BRSV. Calves were vaccinated either by scarification or intratracheally with rVV and challenged 6-7 wk later with BRSV. Although replication of rVV expressing the F protein in the respiratory tract was limited after intratracheal vaccination, the levels of serum and pulmonary antibody were similar to those induced following scarification. The serum antibody response induced by the F protein was biased in favor of IgG1 antibody, whereas the G and the N proteins induced similar levels of IgG1:IgG2, and antibody was undetectable in calves primed with the M2 protein. The F protein induced neutralizing antibodies, but only levels of complement-dependent neutralizing antibodies were induced by the G protein, and antibody induced by the N protein was not neutralizing. The F and N proteins primed calves for BRSV-specific lymphocyte proliferative responses, whereas proliferative responses were detected in calves primed with the G protein only after BRSV challenge. The M2 protein primed lymphocytes in only 1 out of 5 calves. Although there were differences in immune responses induced by the rVVs, the F, G and N, but not the M2, proteins induced protection against BRSV infection and, in contrast with the enhanced lung pathology seen in mice vaccinated with rVV expressing individual proteins of human RSV, there was a reduction in lung pathology in calves.

=> d 13

L10 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002
ACS
AN 1997:775451 CAPLUS
DN 128:60477

L10 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2002
ACS
TI Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of ***bovine*** respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions
AU Taylor, Geraldine; Thomas, Lewis H.; Ferrie, Julie M.; Cool, Roy S.; Wyke, Sara G.; Lenth, Robert; Hardy, Richard; Wertz, Gail W.
CS Institute for Animal Health, Newbury, RG20 7NN, UK
SO Journal of General Virology (1997), 78(12), 3195-3206
CODEN: JGVIAV; ISSN: 0022-1317
PB Society for General Microbiology
IP English
LA English

=> d DOPE/m
4692 DOPE
1033 DOPES
L11 5248 DOPERN
(DOPE OR DOPES)

=> #111 and DMRIE/m
154 DMRIE/RN
(DMRIE)

L12 83 L11 and DMRIE/RN

=> #112 and vaccine
34098 VACCINE
34441 VACCINES
43808 VACCINE
(VACCINE OR VACCINES)

L13 14 L12 AND VACCINE

=> dup rem 113
PROCESSING COMPLETED FOR L13
L14 14 DUP REM L13 (0 DUPLICATES
REMOVED)

=> d 1-14 ii so

L14 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI ***Vaccine*** against foot-and-mouth disease
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L14 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2

L14 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Improved DNA ***vaccines*** for livestock
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L14 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Prevention of myocarditis, abortion and intraventricular infection associated with porcine coronavirus-2
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2

L14 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI cDNAs encoding the Flt-3 receptor ligand and three use as adjuvants in -vector ***vaccines***
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

L14 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Feline calicivirus genes and ***vaccines***, in particular recombinant ***vaccines***
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2

L14 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/ ***DMRIE*** / ***DOPE*** lipid complex
SO Current Opinion in Molecular Therapeutics (2001), 3(1), 70-76
CODEN: CUOTPO; ISSN: 1464-8431

L14 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Porcine coronavirus ***vaccine***
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L14 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI DNA ***vaccines*** against Paramyxoviridae for pets and game animals
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2

L14 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based ***vaccines***
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L14 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: A liposome-mediated gene therapy treatment for bladder cancer
SO Clinical Cancer Research (2000), 6(7), 2913-2920
CODEN: CCREF4; ISSN: 1078-0432

L14 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MNMFEN

L14 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Intratumoral immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMAS; ISSN: 0022-1767

L14 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002
ACS
TI Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes

=> d 12 ab

L14 ANSWER 12 OF 14 CAPLUS COPYRUGHT 2002
ACS
AB A review with 38 refs. discussing the effects of the co-
injection of
lipid vaccine (LP), polyvinyl pyrrolidone (PVP), or
DMRIE :
DOPE cationic liposomes on plasmid DNA-
mediated hepatitis gene
expression and antibody responses to influenza
nucleoprotein (NP) antigen.

=> s DMRIE.DOPE

154 DMRIE

4692 DOPE

1033 DOPES

5248 DOPE

(DOPE OR DOPES)

L15 42 DMRIE.DOPE

(DMRIE/W/DOPE)

=> s I15 and vaccine

34998 VACCINE

34441 VACCINES

43800 VACCINE

(VACCINE OR VACCINES)

L16 4 L15 AND VACCINE

=> d 1-4 to

L16 ANSWER 1 OF 4 CAPLUS COPYRUGHT 2002
ACS
TI Prevention of myocarditis, abortion and listeriosis
infection associated
with porcine circovirus-2
SO PCT Int. Appl., 133 pp
CODEN: PIXXD2

L16 ANSWER 2 OF 4 CAPLUS COPYRUGHT 2002
ACS
TI Immunotherapy of renal cell carcinoma by intratumoral
administration of an
IL-2 cDNA/ ***DMRIE*** / ***DOPE*** lipid
complex
SO Current Opinion in Molecular Therapeutics (2001),
3(1), 70-76
CODEN: CUOTQI; ISSN: 1464-8431

L16 ANSWER 3 OF 4 CAPLUS COPYRUGHT 2002
ACS
TI Adjuvants for plasmid DNA. ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L16 ANSWER 4 OF 4 CAPLUS COPYRUGHT 2002
ACS
TI Intranasal immunization with plasmid DNA-lipid
complexes elicits mucosal
immunity in the female genital and rectal tracts
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMAS; ISSN: 0022-1767

=> d 4 ab

L16 ANSWER 4 OF 4 CAPLUS COPYRUGHT 2002
ACS
AB The development of ***vaccines*** against
pathogens transmitted across
the genito-rectal mucosa that effectively stimulate both
secretory IgA Abs
and cytotoxic T lymphocytes in the genital tract and
CTL in the draining
lymph nodes (LN) has proven a major challenge. Here
we report a novel,
noninvasive approach of genetic vaccination via the
intranasal route.
Such vaccination elicits immune responses in the genital
and rectal
mucosa, draining LNs, and central lymphoid system.
Intranasal
immunization with plasmid DNA-lipid complexes
encoding the model Ag
Brefly luciferase resulted in dissemination of the DNA
and the encoded
transcript throughout the respiratory and gastrointestinal
tracts,
draining LNs, and spleen. Complexing the plasmid
DNA with the lipid
DMRIE / ***DOPE*** enhanced expression
of the encoded protein in
the respiratory tract, increased specific secretory IgA Ab
in the vaginal
and rectal tracts, and increased the circulating levels of
specific IgA
and IgG. In addition, intranasal DNA immunization
resulted in generation of
Ag-specific CTL that were localized in the genital and
cervical LNs and
spleen. These results suggest that intranasal
immunization with plasmid
DNA-lipid complexes may represent a generic
immunization strategy against
pathogens transmitted across the genito-rectal and other
mucosal surfaces.

=> d 4

L16 ANSWER 4 OF 4 CAPLUS COPYRUGHT 2002
ACS
AN 1999:32735 CAPLUS
DN 130:195479
TI Intranasal immunization with plasmid DNA-lipid
complexes elicits mucosal
immunity in the female genital and rectal tracts
AU Khavindis, Linda S.; Barnfield, Christina; Gan,
Liquan; Parkert, Suzanne
CS Department of Immunobiology, Guy's Kings College
and St. Thomas Medical
and Dental Schools, London, SE1 9RT, UK
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMAS; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
RE CNT 60 THERE ARE 60 CITED REFERENCES
AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> s DMRIE and DOPE and delivery

154 DMRIE

4692 DOPE

1033 DOPES

5248 DOPE

(DOPE OR DOPES)

122097 DELIVERY

1277 DELIVERIES

12298 DELIVERY

(DELIVERY OR DELIVERIES)

L17 53 DMRIE AND DOPE AND DELIVERY

=> dup rem 117

PROCESSING COMPLETED FOR L17

L18 52 DUP REM L17 (1 DUPLICATE

REMOVED)

=> s I17 and vaccine

34998 VACCINE

34441 VACCINES

43800 VACCINE

(VACCINE OR VACCINES)

L19 7 L17 AND VACCINE

=> d 1-7

L19 ANSWER 1 OF 7 CAPLUS COPYRUGHT 2002
ACS
AN 2002:10302 CAPLUS
DN 136:74555
TI ***vaccines*** against flu- and mouth disease
IN King, Andrew; Barman, Alison; Andonnet, Jean-
Christophe; Lombard, Michel
PA Marial, Fr
SO PCT Int. Appl., 79 pp
CODEN: PIXXD2
DT Patent
LA French
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 2002000251 A1 20021001 WO 2001-
FR2042 20010637
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG,
BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH,
GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, MQ, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, UY,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ,
UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR, BF,
BI, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE,
SN, TD, TG
FR 2810888 A1 20020104 FR 2000-8437
20000629
AU 2001070678 A5 20020108 AU 2001-70678
20010627
FRAI FR 2000-8437 A 20000629
WO 2001-FR2042 W 20010627
OS MARPAT 136:74555

RE CNT 7 THERE ARE 7 CITED REFERENCES
AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 2 OF 7 CAPLUS COPYRUGHT 2002
ACS
AN 2001:798084 CAPLUS
DN 135:44865
TI Compositions and methods for in vivo
delivery of
polynucleotide-based therapeutics
IN Hantula, Jukka; Salin, Loretta; Manthorpe, Marston
PA Vical Incorporated, USA
SO PCT Int. Appl., 176 pp
CODEN: PIXXD2

DT Patent
LA English
FAN CNT 1

PATENT NO. KIND DATE APPLICATION
NO. DATE
PI WO 2001080897 A2 20011101 WO 2001-
US12975 20010423
W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL,
PT, SE, TR
US 2002019558 A1 20020214 US 2001-839574
20010403
FRAI US 2000-19823P P 20000421
US 2000-253153P P 20001128

L19 ANSWER 3 OF 7 CAPLUS COPYRUGHT 2002
ACS
AN 2001:101291 CAPLUS
DN 134:161880
TI cDNAs encoding the Flt-3 receptor ligand and three
use as adjuvants in
vector ***vaccines***
IN Hermanson, Gary George
PA Vical Inc., USA
SO PCT Int. Appl., 148 pp
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 2001009303 A2 20010208 WO 2000-
US00679 20000731
WO 2001009303 A3 20010816
W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL,
PT, SE
FRAI US 1999-146170P P 19990730

L19 ANSWER 4 OF 7 CAPLUS COPYRUGHT 2002
ACS
AN 2000:900679 CAPLUS
DN 134:54491
TI DNA ***vaccines*** against Paramyxoviridae for
pets and game animals
and their ***delivery*** in liposomes containing
cationic lipids
IN Fischer, Laurent Jean-Charles; Barza-Id, Roux Simona;
Audebert,
Jean-Christophe Francis
PA Marial, Fr
SO PCT Int. Appl., 110 pp
CODEN: PIXXD2
DT Patent
LA French
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 2000077043 A2 20001221 WO 2000-
FR1932 20000608
WO 2000077043 A3 20010719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG,
BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD,
GE, GH, GM, GR, HR, IL,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LC,
LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ,
UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, BF, BI,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN,
TD, TG
FR 2794648 A1 20001215 FR 1999-7604
19990610
BR 2000011732 A 20020305 BR 2000-11732
20000608
EP 1185662 A 20020313 EP 2000-940474
20000608
RE: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL,
LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
FRAI FR 1999-7604 A 19990610
US 1999-144490P P 19990719
WO 2000-FR1992 W 20000608
OS MARPAT 134:54491

L19 ANSWER 5 OF 7 CAPLUS COPYRUGHT 2002
ACS
AN 2000:707018 CAPLUS
DN 133:288556
TI Adjuvant compositions and methods for enhancing
immune responses to
polynucleotide-based ***vaccines***
IN Wheeler, Carl J.
PA Vical Incorporated, USA
SO PCT Int. Appl., 72 pp
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1

PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 200057917 A2 20001005 WO 2000-
US2822 20000324
WO 200057917 A3 20010104
W. CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL,
PT, SE
EP 1165140 A2 20020102 EP 2000-919777
20000324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU,
LU, NL, SE, MC, PT,
IE, FI
PRAI US 1999-126340P P 19990326
WO 2000-US2822 W 20000324

L19 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002
ACS
AN 2000-27482 CAPLUS
DN 134:146025
TI Effectiveness of combined interleukin 2 and B7.1
vaccination strategy is
dependent on the sequence and order: A liposome-
mediated gene therapy
treatment for bladder cancer
AU Larchian, William A.; Horiguchi, Yutaka; Nair, Smita
K.; Fair, William R.;
Heston, Warren D. W.; Gibboa, Eli
CS Department of Urology, The Cleveland Clinic
Foundation, Cleveland, OH
44195, USA
SO Clinical Cancer Research (2000), 6(7), 2913-2920
CODEN: CCRIFA; ISSN: 1078-0432
PB American Association for Cancer Research
DT Journal
LA English
RE CNT 43 THERE ARE 43 CITED REFERENCES
AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002
ACS
AN 1999-679109 CAPLUS
DN 132:148339
TI Adjuvants for plasmid DNA ***vaccines***
AU Norman, Jon; Hartikka, Jukka; Strauch, Pamela;
Manthorpe, Marlene
CS Vical Inc., San Diego, CA, USA
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN
PB Humana Press Inc.
DT Journal, General Review
LA English
RE CNT 38 THERE ARE 38 CITED REFERENCES
AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE
FORMAT

>> d 7 ab

L19 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002
ACS
AB A review with 38 refs. discussing the effects of the co-
injection of
lipoplastic (B₇), polyvinyl pyrrolidone (PVP), or
DMRIE:
DOPE cationic liposomes on plasmid DNA-
mediated luciferase gene
expression and antibody responses to influenza
nucleoprotein (NP) antigen.

>> d bis

(FILE 'HOME' ENTERED AT 13:35:22 ON 03 SEP
2002)

FILE 'CAPLUS' ENTERED AT 13:38:15 ON 03 SEP
2002

L1 5 S 154486-25-6/RN
L2 154 S DMRIE/RN
L3 19 S L2 AND VACCINE
L4 1 S L3 AND RSV
L5 5 S 153112-64-2/RN OR 154486-25-6/RN
L6 105 S 153112-64-2/RN OR 154486-25-6/RN
L7 5 S L6 AND (RSV OR BRSV)
L8 4 DUP REM L7 (1 DUPLICATE REMOVED)
L9 191 S RSV (S) VACCINE
L10 21 S L9 AND (BOVINE OR COW)
L11 3248 S DOPE/RN
L12 83 S L11 AND DMRIE/RN
L13 14 S L12 AND VACCINE
L14 14 DUP REM L13 (0 DUPLICATES
REMOVED)
L15 42 S DMRIE-DOPE
L16 4 S L15 AND VACCINE
L17 53 S DMRIE AND DOPE AND DELIVERY
L18 53 DUP REM L17 (1 DUPLICATE
REMOVED)
L19 7 S L17 AND VACCINE

>> i 117 (and (vaccine or gene delivery or gene therapy)
34998 VACCINE
34441 VACCINES
43000 VACCINE
(VACCINE OR VACCINES)
717656 GENE
270831 GENES

759543 GENE
(GENE OR GENES)
122097 DELIVERY
1277 DELIVERIES
122908 DELIVERY
(DELIVERY OR DELIVERIES)
3749 GENE DELIVERY
(GENE/DELIVERY)
717656 GENE
270831 GENES
759543 GENE
(GENE OR GENES)
175374 THERAPY
10179 THERAPIES
180867 THERAPY
(THERAPY OR THERAPIES)
25281 GENE THERAPY
(GENE/WTHERAPY)
L20 34 L17 AND (VACCINE OR GENE DELIVERY
OR GENE THERAPY)
>> d 1-20 ii so

L20 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Transfection with fluorinated lipoplexes based on
fluorinated analogues of
DOTMA, ***DMRIE*** and DPPE
SO Biochimica et Biophysica Acta (2002), 1564(2), 349-
358
CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI ***Vaccine*** against foot-and-mouth disease
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2

L20 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Compositions and methods for in vivo
delivery of
poly(nucleotide-based) therapeutics
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2

L20 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI High-throughput screening method for identification of
new lipofection
reagents
SO Journal of Biomolecular Screening (2001), 6(4), 245-
254
CODEN: JBISFJ; ISSN: 1087-0571

L20 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Phase II study of direct intrasplenic gene transfer of
aloelectin-7, an
HLA-B*7:beta 2-microglobulin DNA-liposome
complex, in patients with
metastatic melanoma
SO Clinical Cancer Research (2001), 7(8), 2285-2291
CODEN: CCRIFA; ISSN: 1078-0432

L20 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Luventis (Vical Inc)
SO Current Opinion in Investigational Drugs
(PharmaPress Ltd.) (2001), 2(7),
976-981
CODEN: COIDAZ

L20 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Efficiency and Toxicity of Liposome-mediated Gene
Transfer to Corneal
Endothelial Cells
SO Experimental Eye Research (2001), 73(1), 1-7
CODEN: EXERA6; ISSN: 0014-4835

L20 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Intravesical interleukin-2 ***gene***
therapy is orthotopic
mouse model of bladder cancer
SO Kito Ikuta (2001), 78(2), 7177-7187
CODEN: KJHJAS; ISSN: 0368-5179

L20 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI cDNAs encoding the Flt-3 receptor ligand and there
use as adjuvants in
vector ***vaccines***
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

L20 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Peptide-lipid conjugation, liposomes and liposomal drug
delivery
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2

L20 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI DNA ***vaccines*** against Paramyxoviridae for
pets and game animals
and their ***delivery*** in liposomes containing
cationic lipids
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2

L20 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Novel compositions useful for delivering anti-
inflammatory agents into a
cell
SO Eur. Pat. Appl., 78 pp.
CODEN: EPXDXW

L20 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Adjuvant compositions and methods for enhancing
immune responses to
polynucleotide-based ***vaccines***
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L20 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Effectiveness of combined interleukin 2 and B7.1
vaccination strategy is
dependent on the sequence and order: A liposome-
mediated ***gene***
therapy treatment for bladder cancer
SO Clinical Cancer Research (2000), 6(7), 2913-2920
CODEN: CCRIFA; ISSN: 1078-0432

L20 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Intravesical liposome-mediated interleukin-2
gene
therapy in orthotopic murine bladder cancer
model
SO Gene Therapy (2000), 7(10), 844-851
CODEN: GETHEC; ISSN: 0969-7128

L20 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Cationic liposome-mediated expression of HIV-
regulated luciferase and
diphtheria toxin A genes in HeLa cells infected with or
expressing HIV
SO Biochimica et Biophysica Acta (1997), 1356(2), 185-
197
CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Dry-powder compositions and methods for nucleic acid
delivery to
the lung
SO U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 417,507,
abandoned.
CODEN: USXXAM

L20 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Lipid-nucleic acid particles prepared via a hydrophobic
lipid-nucleic acid
complex intermediate and use for gene transfer
SO U.S., 63 pp., Cont.-in-part of U.S. 5,705,385.
CODEN: USXXAM

L20 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L20 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Plasmids suitable for antitumor ***gene***
therapy
SO U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 74,344,
abandoned.
CODEN: USXXAM

>> d 18

L20 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2002
ACS
AN 1999-704853 CAPLUS
DN 131:314184
TI Lipid-nucleic acid particles prepared via a hydrophobic
lipid-nucleic acid
complex intermediate and use for gene transfer
DN Wheeler, Jeffrey J.; Bally, Marcel B.; Zhang, Yum-
Peng; Reimer, Dorothy
L.; Hope, Michael; Cullis, Peter R.; Scherrer, Peter
FA In: Pharmaceutics Corp., Can.
SO U.S., 63 pp., Cont.-in-part of U.S. 5,705,385.
CODEN: USXXAM
DT Patent
LA English
FAN CNT 2

PATENT NO. KIND DATE APPLICATION
NO. DATE

PI US 5796567 A 19991102 US 1996-660025
19960606
US 5795285 A 19980106 US 1995-455458
19950607
US 5981501 A 19991109 US 1995-454282
19950607
CA 2222328 AA 19961219 CA 1996-222238
19960606
PRAI US 1995-484282 A2 19950607
US 1995-454282 A2 19950607
RE CNT 41 THERE ARE 41 CITED REFERENCES
AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

>0 d 18 d 21-34 u s o
'IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AL, PRAI
BIB ----- AN, plus Bibliographic Data and PI table
(default)
CAN ----- List of CA abstract numbers without answer
numbers
CIBB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family
data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no
answer numbers;
SCAN must be entered on the same line as the
DISPLAY,
c.g. D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indexed with text labels
IALL ----- ALL, indexed with text labels
IBIB ----- BIB, indexed with text labels
IMAX ----- MAX, indexed with text labels
ISTD ----- STD, indexed with text labels
OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indexed with text labels
SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations
HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST
and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index
name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index
name, its
structure diagram, plus NTE and SEQ fields
PHITSTR ----- First HIT RN, its text modification, its CA
index name, and
its structure diagram
PHITSEQ ----- First HIT RN, its text modification, its CA
index name, its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in
which it occurs

To display a particular field or fields, enter the display field
codes. For a list of the display field codes, enter HELP
DFIELDS at
an arrow prompt (>). Examples of formats include: TI,
TIAU, BIB, ST,
TLIND, TLISO. You may specify the format fields in any
order and the
information will be displayed in the same order as the
format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND,
HITRN, HITSTR,
PHITSTR, HITSEQ, PHITSEQ, KWIC, and OCC) may be
used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):

L20 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Lipid-nucleic acid particles prepared via a hydrophobic
lipid-nucleic acid
complex intermediate and use for gene transfer

L20 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Immunotherapy of established tumors in mice by
intratumoral injection of
interleukin-2 plasmid DNA: induction of CD8+ T-cell
immunity

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Construction of cationic lipid complex-
polynucleotides-conjug liposomes for
gene ***delivery*** to mucosal epithelium
for immunization or
therapeutic purposes

L20 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Dry powder formulations of polynucleotide complexes
for inhalation
delivery to the respiratory tract

L20 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Enhanced in vitro and in vivo ***gene***
delivery using
cationic agent complexed retrovirus vectors

L20 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Electrostatic parameters of cationic liposomes
commonly used for
gene ***delivery*** as determined by 4-
heptadecyl-7-
hydroxycoumarin

L20 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Cationic liposome-mediated expression of HIV-
regulated luciferase and
diphtheria toxin A genes in HeLa cells infected with or
expressing HIV

L20 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Pulmonary surfactant inhibits cationic liposome-
mediated ***gene***
delivery to respiratory epithelial cells in vitro

L20 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Stabilization of polynucleotide complexes
with transfecting components

L20 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Separation of active complexes from mixtures of
polynucleotides associated
with transfecting components

L20 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Single-vial formulations of DNA/lipid complexes

L20 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI A new cationic liposome DNA complex enhances the
efficiency of arterial
gene transfer in vivo

L20 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI ***Delivery*** of DNA-cationic liposome
complexes by small-particle
aerosol

L20 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Cancer ***gene*** ***therapy*** using plasmid
DNA: safety
evaluation in rodents and non-human primates

L20 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Safety and short-term toxicity of a novel cationic lipid
formulation for
human ***gene*** ***therapy***

>0 d 21-34 u s o
L20 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Immunotherapy of established tumors in mice by
intratumoral injection of
interleukin-2 plasmid DNA: induction of CD8+ T-cell
immunity

SO Cancer Gene Therapy (1998), 5(5), 321-330
CODEN: CGTNEG; ISSN: 0929-1903
L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Construction of cationic lipid complex-
polynucleotides-conjug liposomes for
gene ***delivery*** to mucosal epithelium
for immunization or
therapeutic purposes

SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2

L20 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Dry powder formulations of polynucleotide complexes
for inhalation
delivery to the respiratory tract

SO U.S., 31 pp., Cont. in-part of U.S. Ser. No. 482,110.
CODEN: USXXAM

L20 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Enhanced in vitro and in vivo ***gene***
delivery using
cationic agent complexed retrovirus vectors

SO Gene Therapy (1998), 5(9), 1180-1186
CODEN: GETHEG; ISSN: 0969-7128
L20 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Electrostatic parameters of cationic liposomes
commonly used for
gene ***delivery*** as determined by 4-
heptadecyl-7-
hydroxycoumarin

SO Biochimica et Biophysica Acta (1997), 1329(2), 211-
222

CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Cationic liposome-mediated expression of HIV-
regulated luciferase and
diphtheria toxin A genes in HeLa cells infected with or
expressing HIV

SO Biochimica et Biophysica Acta (1997), 1356(2), 185-
197
CODEN: BBACAQ; ISSN: 0006-3002

L20 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Pulmonary surfactant inhibits cationic liposome-
mediated ***gene***
delivery to respiratory epithelial cells in vitro

SO Human Gene Therapy (1997), 6(4), 431-438
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Stabilization of polynucleotide complexes
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

L20 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Separation of active complexes from mixtures of
polynucleotides associated
with transfecting components

SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2

L20 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Single-vial formulations of DNA/lipid complexes
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2

L20 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI A new cationic liposome DNA complex enhances the
efficiency of arterial
gene transfer in vivo

SO Human Gene Therapy (1996), 7(15), 1803-1812
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI ***Delivery*** of DNA-cationic liposome
complexes by small-particle
aerosol

SO Human Gene Therapy (1996), 7(6), 731-741
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Cancer ***gene*** ***therapy*** using plasmid
DNA: safety
evaluation in rodents and non-human primates

SO Human Gene Therapy (1995), 6(5), 575-590
CODEN: HGTHE3; ISSN: 1043-0342

L20 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2002
ACS
TI Safety and short-term toxicity of a novel cationic lipid
formulation for
human ***gene*** ***therapy***

SO Hum. Gene Ther. (1993), 4(6), 781-8
CODEN: HGTHE3; ISSN: 1043-0342

>0 d 22
L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002
ACS
AN 1998:621321 CAPLUS
DN 129-235638

TI Construction of cationic lipid complex-
polynucleotides-conjug liposomes for
gene ***delivery*** to mucosal epithelium
for immunization or
therapeutic purposes

IN Davis, Heather Lynn; Jeejee, Joel; Gebeyehu, Gulliat
PA Can.
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN, CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 984099 A1 19980917 WO 1997-
US3421 19970310
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GR, HA, HU, IL, IS, JP, KE,
KG, KP, KR, KZ,

LC, LR, LU, LS, LT, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, TL, TM, TR, TT,
UA, UG, US, UZ,
VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW, GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH,
DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NI, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG
AU 9719871 A1 19980929 AU 1997-19871
19970310

=> d 22 ab

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002

ACS

AB Disclosed are compes. and method for transferring

mammalian mucosal

epithelia with nucleic acid/cationic lipid complexes

The nucleic

acid/cationic lipid complex may be administered, for

example,

intranasally or directly into the lungs. The best results

are obtained

when the lipid mixed with the max. amt. of DNA that it

can complex. Thus,

cationic lipids are complexed with a polynucleotides

coding for

immunogenic antigens in mice. Hybridomas are

constructed by fusing

B-lymphocytes with myeloma cells, and pos. clones are

selected which

produce anti-immunogen antibody. Suitable cationic

lipids include DOTMA,

DOTAP, and DORI-esters. Neutral lipids that can be

used include

lecithins, phosphatidylethanolamine,

phosphatidylcholine (e.g.

DOPE, OPPE), and

diacylglycerolphosphatidylethanolamine. Cationic

sterol derivs., such as DC-Chol can also be used. Polyclonal

and

monoclonal antibodies and antisense oligonucleotides

are also claimed

effective to ***gene*** ***therapy***. The

method is tested in a

mouse system.

=> d 22 kwic

L20 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2002

ACS

TI Construction of cationic lipid complex-

polynucleotides-contg liposomes for

gene ***delivery*** to mucosal epithelium

for immunization or

therapeutic purposes

AB . . . antibody. Suitable cationic lipids include

DOTMA, DOTAP, and

DORI-esters. Neutral lipids that can be used include

lecithins,

phosphatidylethanolamine, phosphatidylcholine

(e.g.

DOPE,

OPPE), and diacylglycerolphosphatidylethanolamine.

Cationic sterol derivs.,

such as DC-Chol can also be used. Polyclonal and

monoclonal antibodies

and antisense oligonucleotides are also claimed effective

to ***gene*** ***therapy***. The method is tested in a

mouse system.

ST cationic lipid DNA mucosal epithelium transfection;

gene

delivery liposome cationic lipid

IT Immunization

(DNA-based; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT DNA

RL: BPR (Biological process); BSU (Biological study,

unclassified); BIU (Biological use, unclassified); THU (Therapeutic use);

BIOL (Biological study); PROC (Process); USES (Uses)

(cationic lipid complexes with; construction of

cationic lipid complex-polynucleotides-contg liposomes for

gene

delivery to mucosal epithelium for

immunization or therapeutic

purposes)

IT Lipids, biological studies

RL: BIU (Biological use, unclassified); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)

(cationic; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT Drug ***delivery*** systems

Gene ***therapy***

Hybridoma

Mammal (Mammalia)

Mouse

Transformation, genetic

(construction of cationic lipid complex-

for ***gene*** ***delivery*** to mucosal

epithelium for

immunization or therapeutic purposes)

IT Antisense oligonucleotides

RL: BAC (Biological activity or effector, except

adverse); BSU (Biological study, unclassified); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)

(construction of cationic lipid complex-

polynucleotides-contg liposomes

for ***gene*** ***delivery*** to mucosal

epithelium for

immunization or therapeutic purposes)

IT Antigens

RL: BOC (Biological occurrence); BSU (Biological study,

unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU

(Occurrence); USES (Uses)

(construction of cationic lipid complex-

polynucleotides-contg liposomes

for ***gene*** ***delivery*** to mucosal

epithelium for

immunization or therapeutic purposes)

IT Lecitins

RL: BPR (Biological process); BSU (Biological study,

unclassified); BIU (Biological use, unclassified); THU (Therapeutic use);

BIOL (Biological study); PROC (Process); USES (Uses)

(construction of cationic lipid complex-

polynucleotides-contg liposomes

for ***gene*** ***delivery*** to mucosal

epithelium for

immunization or therapeutic purposes)

IT ***Gene***

RL: BPR (Biological process); BSU (Biological study,

unclassified); THU (Therapeutic use); BIOL (Biological study); PROC

(Process); USES (Uses)

(***delivery*** system; construction of cationic

lipid

complex-polynucleotides-contg liposomes for

gene

delivery to mucosal epithelium for

immunization or therapeutic

purposes)

IT Mucous membrane

(epithelial; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT Lung

(epithelium; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT Drug ***delivery*** systems

(liposomes; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT Antibodies

RL: ARG (Analytical reagent use); THU (Therapeutic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(monoclonal; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT Lipids, biological studies

RL: BIU (Biological use, unclassified); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)

(neutral; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT Lung disease

(treatment of; construction of cationic lipid complex-

polynucleotides-contg liposomes for ***gene*** ***delivery***

to mucosal

epithelium for immunization or therapeutic purposes)

IT ***Delivery*** systems

Gene ***therapy***

189203-04-1, Cellfexin

189203-05-2, ***Dutic*** -C 21893-18-0

21893-19-1 21893-20-4

21893-21-5 21893-22-6 21893-23-7 21893-25-

9 21893-26-0

21893-28-2 21893-29-3 21893-30-6 21900-70-

4

RL: BAC (Biological activity or effector, except

adverse); BSU (Biological study, unclassified); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(construction of cationic lipid complex-

polynucleotides-contg liposomes

for ***gene*** ***delivery*** to mucosal

epithelium for

immunization or therapeutic purposes)

IT 57-88-5, Cholesterol, biological studies

RL: BAC (Biological activity or effector, except

adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES

(Uses)

(construction of cationic lipid complex-

polynucleotides-contg liposomes

for ***gene*** ***delivery*** to mucosal

epithelium for

immunization or therapeutic purposes)

IT 4317-76-2, Diacetylphosphatidylethanolamine

194162-48-3, Dotum

144189-73-1, Dotap

RL: BPR (Biological process); BSU (Biological study,

unclassified); BIU (Biological use, unclassified); THU (Therapeutic use);

BIOL (Biological study); PROC (Process); USES (Uses)

(construction of cationic lipid complex-

polynucleotides-contg liposomes

for ***gene*** ***delivery*** to mucosal

epithelium for

immunization or therapeutic purposes)

=> s DMRIE (S) DOPE and (vaccine or delivery)

154 DMRIE

4692 DOPE

1033 DOPE

5248 DOPE

(DOPE OR DOPES)

49 DMRIE (S) DOPE

34998 VACCINE

34441 VACCINES

43800 VACCINE

(VACCINE OR VACCINES)

122997 DELIVERY

1277 DELIVERIES

122908 DELIVERY

(DELIVERY OR DELIVERIES)

L21 28 DMRIE (S) DOPE AND (VACCINE OR

DELIVERY)

=> dup rem 128

L28 IS NOT VALID HERE

The L-number entered has not been defined in this session.

or it

has been deleted. To see the L-numbers currently defined

in this

session, enter DISPLAY HISTORY at an arrow prompt

(=)

=> dup rem 121

PROCESSING COMPLETED FOR L21

L22 28 DUP REM L21 (0 DUPLICATES

REMOVED)

=> d 1-28 ti so

L22 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002

ACS

TI Prevention of myocardial infarction and intravascular

infection associated

with porcine coronavirus-2

SO PCT Int. Appl., 133 pp

CODEN: PXXXX2

L22 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2002

ACS

TI Phase II study of direct intravenous gene transfer of

adenovect-7, an

HLA-97 beta 2-microglobulin DNA-liposome

complex, in patients with

metastatic melanoma

SO Clinical Cancer Research (2001), 7(8), 2285-2291

CODEN: CCRF4J, ISSN: 1078-0432

L22 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2002

ACS

TI Leventin(Vical Inc)

SO Current Opinion in Investigational Drugs

(PharmPress Ltd.) (2001), 2(7),

976-981

CODEN: COIDAZ

L22 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002

ACS

TI Interleukin-2 gene therapy in orthotopic

mouse model of

bladder cancer

SO Kato Iguchi (2001), 78(2), 1177-1187

CODEN: KEGAS, ISSN: 0368-5179

L22 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2002

ACS

TI Immunotherapy of renal cell carcinoma by intratumoral

SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L22 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Peptide-enhanced cationic lipid transfections
SO U.S., 102 pp., Cont.-in-part of U.S. 5,756,392.
CODEN: USXXAM

L22 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model
SO Gene Therapy (2000), 7(10), 844-851
CODEN: GETHEG, ISSN: 0969-7128

L22 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Adjuvants for plasmid DNA ***vaccines***
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L22 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Antisense oligonucleotides increase the apoptotic effect of idarubicin in the K-562 cell line
SO Medicina (Buenos Aires) (2000), 60(1), 143-145
CODEN: MEDCAD, ISSN: 0025-7680

L22 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft
SO Cellular Immunology (2000), 204(2), 96-104
CODEN: CLIMB8, ISSN: 0008-4749

L22 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
SO Journal of Immunology (1999), 163(12), 6378-6385
CODEN: JOIMAS, ISSN: 0022-1767

L22 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Levonectin (Vical Inc)
SO Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs (1999), 1(3), 324-332
CODEN: CODDF2, ISSN: 1464-8466

L22 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
SO Journal of Immunology (1999), 162(1), 254-262
CODEN: JOIMAS, ISSN: 0022-1767

L22 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 The use of temperature to control the size of cationic liposome/plasmid DNA complexes
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

L22 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Increasing the efficiency of uptake of transforming DNA complexes with polycationic steric peptides
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

L22 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity
SO Cancer Gene Therapy (1999), 5(5), 321-330
CODEN: CGTHEG, ISSN: 0929-1903

L22 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 ***Delivery*** of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes
SO Biochimica et Biophysica Acta (1998), 1372(1), 55-68
CODEN: BBACAR, ISSN: 0006-3002

L22 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Pulmonary surfactant inhibits cationic liposome-mediated gene ***delivery*** to respiratory epithelial cells in vitro
SO Human Gene Therapy (1997), 8(4), 431-438
CODEN: HGTHIE3, ISSN: 1043-0342

L22 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7

SO Gene Therapy (1997), 4(5), 419-425
CODEN: GETHEG, ISSN: 0969-7128

L22 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival
SO Biochemical and Biophysical Research Communications (1997), 233(2), 359-364
CODEN: BBACAR, ISSN: 0006-291X

L22 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Electrostatic parameters of cationic liposomes commonly used for gene ***delivery*** as determined by 4-heptadecyl-7-hydroxycoumarin
SO Biochimica et Biophysica Acta (1997), 1329(2), 211-222
CODEN: BBACAR, ISSN: 0006-3002

L22 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Single-vial formulations of DNA/lipid complexes
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2

L22 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo
SO Human Gene Therapy (1996), 7(15), 1803-1812
CODEN: HGTHIE3, ISSN: 1043-0342

L22 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 ***Delivery*** of DNA-cationic liposome complexes by small-particle aerosol
SO Human Gene Therapy (1996), 7(6), 731-741
CODEN: HGTHIE3, ISSN: 1043-0342

L22 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates
SO Human Gene Therapy (1995), 6(5), 575-90
CODEN: HGTHIE3, ISSN: 1043-0342

L22 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2002
ACS
T1 Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy
SO Hum. Gene Ther. (1993), 4(6), 781-8
CODEN: HGTHIE3, ISSN: 1043-0342

==>

==> log off

ALL L22 ANSWERS AND ANSWER SETS ARE

DELETED AT LOGOFF

LOGOFF(Y)N)HOLD Y

STN INTERNATIONAL LOGOFF AT 14:31:14 ON 03

SEP 2002